Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cipla Ltd ( (IN:CIPLA) ) has shared an update.
Cipla Ltd has announced that the USFDA inspection at its subsidiary Medispray Laboratories’ manufacturing facility in Kundaim, Goa, has been classified as Voluntary Action Indicated (VAI). This classification suggests that while there are some issues, they are not critical, and the company is taking this disclosure as part of its commitment to good governance practices.
More about Cipla Ltd
Cipla Ltd is a prominent pharmaceutical company based in India, known for its wide range of pharmaceutical products and services. The company focuses on providing affordable and high-quality medicines across various therapeutic categories, serving both domestic and international markets.
YTD Price Performance: -2.24%
Average Trading Volume: 38,062
Current Market Cap: 1196.4B INR
Find detailed analytics on CIPLA stock on TipRanks’ Stock Analysis page.